Expanding field of purinergic signaling
Expanding field of purinergic signaling
复制标题
DOI：
10.1002/ddr.1093
复制
发表时间：
2001-01-01
影响因子：
3.8
通讯作者：
Burnstock, G
中科院分区：
文献类型：
--
作者：
Burnstock, G
这篇文章试图描绘一个广泛的画面，在嘌呤能信号领域的爆炸性的最新发展。在简要回顾了嘌呤受体亚型的历史和更新之后，重点是嘌呤和嘧啶的生理作用。从神经传递、分泌和血管舒张的短期信号和发育、再生、增殖和细胞死亡的长期（营养）信号两方面考虑。营养信号传导的例子包括肢体芽软骨发育、神经胶质细胞增殖、骨骼肌发育、平滑肌表型受体表达变化、睾丸精细胞成熟和骨重塑。本文描述了病理条件下嘌呤受体表达的可塑性，包括间质性膀胱炎和流出梗阻时副交感神经控制膀胱嘌呤能成分的增加，高血压大鼠血管交感共递质控制，糖尿病和转基因高血压动物模型肾小球中P2X(7)受体的出现。充血性心力衰竭大鼠心脏中P2X(1)和P2Y(2)受体mRNA表达上调。本文考虑了P2X(3)受体在痛觉中的作用，并探讨了肠道嘌呤能机械感觉传导的新假设。本文总结了一些成熟的未来发展领域的个人观点，包括对可能导致嘌呤能治疗剂发展的不同策略的讨论。药物开发，2001,21(2):1-10。(C) 2001 WiIey-Liss, Inc。
This article attempts to paint a broad picture of the extraordinary explosive recent developments in the purinergic signaling field. After a brief historical review and update of purinoceptor subtypes, the focus is on the physiological roles of purines and pyrimidines. These are considered both in terms of short-term signaling in neurotransmission, secretion, and vasodilatation and in long-term (trophic) signaling in development, regeneration, proliferation, and cell death. Examples of trophic signaling include cartilage development in limb buds, glial cell proliferation, development of skeletal muscle, changes in receptor expression in smooth-muscle phenotypes, maturation of testicular spermatids, and bone remodeling. Plasticity of purinoceptor expression in pathological conditions is described, including the increase in the purinergic component of parasympathetic nervous control of the human bladder in interstitial cystitis and outflow obstruction and in sympathetic cotransmitter control of blood vessels in hypertensive rats, the appearance of P2X(7) receptors in the glomeruli of the kidney from diabetic and transgenic hypertensive animal models, and up-regulation of P2X(1) and P2Y(2) receptor mRNA in hearts of rats with congestive heart failure. The role of P2X(3) receptors in nociception is considered, and a new hypothesis about purinergic mechanosensory transduction in the gut is explored. A personal view of some of the areas ripe for future development concludes this article, including a discussion of different strategies that could lead to the development of purinergic therapeutic agents. Drug Dev. Res. 52:1-10, 2001. (C) 2001 WiIey-Liss, Inc.